Synthetic transcription factor engineering for cell and gene therapy

Area of Science:

• Synthetic biology
• Gene therapy
• Molecular engineering

Background:

• Synthetic transcription factors (synTFs) are crucial for controlling transgene expression in cell and gene therapy.
• Current reliance on non-human synTF components raises concerns regarding immunogenicity and drug properties.
• Progress in synTF development has been hindered by these safety and efficacy challenges.

Purpose of the Study:

• To address the limitations of non-human synTF components.
• To highlight recent advances in developing human-derived synTFs.
• To discuss the potential of novel control modules and circuit designs for clinical translation.

Main Methods:

• Engineering human-derived DNA-binding domains (DBDs) and transcriptional activation domains (TADs).
• Developing novel control modules responsive to clinically approved small molecules.
• Designing complex, multi-input synTF circuits and controllers inducible by autonomous signaling inputs.

Main Results:

• Successful pairing of human-derived DBDs and TADs with new control modules.
• Development of advanced synTF architectures, including autonomous and multi-input systems.
• Demonstration of advanced control strategies in clinically relevant vectors and in vivo models.

Conclusions:

• Human-derived synTFs can overcome immunogenicity and drug property concerns.
• Novel control modules and complex circuits enhance the safety and efficacy of synTF technology.
• Further validation in clinical settings is essential for advancing synTF-based therapies.